Welcome to LookChem.com Sign In|Join Free

CAS

  • or

3834-43-3

Ethyl 2-amino-4,4,4-trifluorobutanoate hydrochloride is a chemical compound with the molecular formula C6H10ClF3NO2. It is a derivative of 2-amino-4,4,4-trifluorobutanoic acid, featuring an ethyl ester group attached to the carboxylic acid moiety. ethyl 2-amino-4,4,4-trifluorobutanoate hydrochloride is known for its potential applications in the synthesis of pharmaceuticals and agrochemicals, particularly as a building block for the development of new drugs and pesticides. The hydrochloride salt form enhances its solubility and stability, which can be beneficial for certain chemical reactions and formulations. The trifluoromethyl groups in the molecule contribute to its unique reactivity and properties, making it a valuable intermediate in organic synthesis.

3834-43-3 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 3834-43-3 Structure

  • Basic information

    1. Product Name: ethyl 2-amino-4,4,4-trifluorobutanoate hydrochloride
    2. Synonyms:
    3. CAS NO:3834-43-3
    4. Molecular Formula:
    5. Molecular Weight: 221.607
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 3834-43-3.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: ethyl 2-amino-4,4,4-trifluorobutanoate hydrochloride(CAS DataBase Reference)
    10. NIST Chemistry Reference: ethyl 2-amino-4,4,4-trifluorobutanoate hydrochloride(3834-43-3)
    11. EPA Substance Registry System: ethyl 2-amino-4,4,4-trifluorobutanoate hydrochloride(3834-43-3)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 3834-43-3(Hazardous Substances Data)

3834-43-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 3834-43-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,8,3 and 4 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 3834-43:
(6*3)+(5*8)+(4*3)+(3*4)+(2*4)+(1*3)=93
93 % 10 = 3
So 3834-43-3 is a valid CAS Registry Number.

3834-43-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 2-amino-4,4,4-trifluorobutanoate hydrochloride

1.2 Other means of identification

Product number -
Other names 1-ethoxy-4,4,4-trifluoro-1-oxobutan-2-aminium chloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:3834-43-3 SDS

3834-43-3Relevant articles and documents

A short and efficient synthesis of 3-[2,2,2-trifluoroethyl]hexahydro-2H-1, 4-diazepin-2-one

Balsells, Jaume,Waters, Marjorie,Hansen, Karl,Kieczykowski, Gerard R.,Song, Zhiguo J.

, p. 2779 - 2781 (2007)

A short, high yielding, five-step synthesis of the pharmaceutically interesting fluorinated heterocycle, 3-[2,2,2-trifluoroethyl]hexahydro-2H-1,4- diazepin-2-one, has been developed. Georg Thieme Verlag Stuttgart.

PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE

-

Page/Page column 67; 68, (2011/07/09)

The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

PROCESS TO CHIRAL BETA AMINO ACID DERIVATIVES BY ASYMMETRIC HYDROGENATION

-

Page/Page column 19, (2010/11/08)

The present invention relates to a process for the efficient preparation of enantiomerically enriched beta amino acid derivatives which are useful in the asymmetric synthesis of biologically active molecules. The process comprises an enantioselective hydrogenation of a prochiral beta amino acrylic acid derivative substrate in the presence of a transition metal precursor complexed with a chiral ferrocenyl diphosphine ligand with in situ protection of the primary amine product. The invention also relates to a novel process for the preparation of chiral beta-amino acid amides as inhibitors of the dipeptidyl peptidase-IV of structural formula III and the useful intermediates obtained therein. The products resulting from the instant process are inhibitors of dipeptidyl peptidase-IV and thereby useful for the treatment of Type 2 diabetes.

TARTARIC ACID SALTS OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR

-

Page/Page column 8, (2008/06/13)

Tartaric acid salts of (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl) butanoyl]hexahydro-3-(2,2,2-trifluoroethyl)-2H-1,4-diazepin-2-one are potent inhibitors of dipeptidyl peptidase-IV and are useful for the prevention and/or treatment of non-insulin depe

CGRP RECEPTOR ANTAGONISTS

-

Page/Page column 110-111, (2010/11/08)

Compounds of Formula (I): and Formula (II): (where variables R2, R4, A, B, D, W, X, Y and Z are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 3834-43-3